In addition, in myeloproliferative neoplasms, the loss of PTCH2, and, consequently, Shh pathway activation, it was shown to improve tumor resistance to Fluorouracil (5-FU) treatment [35]. This evidence concerns the gene PTCH2 and myeloproliferative neoplasm.